Driehaus Capital CDXS Position
ExitedDriehaus Capital exited their position in CODEXIS, INC. (CDXS) in Q1 2025, after holding the stock for 2 quarters.
The position was first reported in Q4 2024 and has been tracked across 2 quarterly 13F filings.
1 other tracked fund also holds CDXS.
Short interest stands at 12.0% of float with 2.5 days to cover, indicating significant bearish positioning against the stock.
About CODEXIS, INC.
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Full company profile →Short Interest
12.0%
2.5 days to cover
Driehaus Capital CDXS Position History
Frequently Asked Questions
Does Driehaus Capital own CDXS?
No. Driehaus Capital exited their position in CODEXIS, INC. (CDXS) in Q1 2025. They previously held the stock for 2 quarters.
How many hedge funds own CDXS?
1 specialist biotech hedge fund currently holds CDXS, including Casdin Capital. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Driehaus Capital first buy CDXS?
Driehaus Capital's position in CDXS was first reported in Q4 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Driehaus Capital's CDXS position increasing or decreasing?
Driehaus Capital completely exited their CDXS position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
CDXSCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Driehaus CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →